Krill Oil and Muscle in Older Adults
Effects of Krill Oil Supplementation on Muscle Function in Older Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Glasgow, United Kingdom
- Stuart Robert Gray
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI less than 35kg/m2
Exclusion Criteria:
- Diabetes
- severe cardiovascular disease
- seizure disorders
- uncontrolled hypertension (>150/90mmHg at baseline measurement)
- cancer or cancer that has been in remission <5 years
- ambulatory impairments which would limit ability to perform assessments of muscle function
- dementia
- taking medication known to affect muscle (e.g. steroids)
- have an implanted electronic device (e.g. pacemaker/defibrillator/insulin pump)
- on anticoagulant therapy
- allergies to seafood
- regular consumption of more than 2 portions of oily fish per week.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
4g/day of mixed vegetable oil supplements
|
Mixed vegetable oil
|
|
EXPERIMENTAL: Krill
4g/day krill oil
|
Aker Biomarine Superba Krill Oil
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Muscle strength
Time Frame: Change from baseline to 6 months
|
knee extensor muscle strength
|
Change from baseline to 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Grip strength
Time Frame: Change from baseline to 6 months
|
Grip strength
|
Change from baseline to 6 months
|
|
Change in Muscle thickness
Time Frame: Change from baseline to 6 months
|
Vastus lateralis muscle thickness
|
Change from baseline to 6 months
|
|
Change in Short performance physical battery test
Time Frame: Change from baseline to 6 months
|
SPPB
|
Change from baseline to 6 months
|
|
Change in Body Fat
Time Frame: Change from baseline to 6 months
|
Measured by BIA
|
Change from baseline to 6 months
|
|
Change in Lean Mass
Time Frame: Change from baseline to 6 months
|
Measured by BIA
|
Change from baseline to 6 months
|
|
Change in Fasting glucose
Time Frame: Change from baseline to 6 months
|
Fasting glucose
|
Change from baseline to 6 months
|
|
Change in Blood lipids
Time Frame: Change from baseline to 6 months
|
Blood lipids
|
Change from baseline to 6 months
|
|
Change in CRP
Time Frame: Change from baseline to 6 months
|
CRP
|
Change from baseline to 6 months
|
|
Change in Erythrocyte fatty acid profile
Time Frame: Change from baseline to 6 months
|
Erythrocyte fatty acid profile
|
Change from baseline to 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stuart Gray, PhD, University of Glasgow
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 200170067
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
NCT07399301Not yet recruiting
-
NCT07291765RecruitingSarcopenia in Elderly
-
NCT07538674Not yet recruitingSarcopenia in Elderly
-
NCT07482163Not yet recruiting
-
NCT06942182Not yet recruitingFrailty | Sarcopenia in Elderly | Frailty/Sarcopenia | Frailty in Older Adults
-
NCT07315789CompletedSarcopenia in Elderly | Institutionalized Older Adults | HIIT
-
NCT07072195RecruitingSarcopenia | Sarcopenia in Elderly
-
NCT06986395Not yet recruitingSarcopenia in Elderly
-
NCT05276921Completed
-
NCT07127692Not yet recruitingFalls | Sarcopenia in Elderly
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT06767540Not yet recruiting
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT04388215UnknownHypertension | Dyslipidemias